Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Shanker, Anil

One or more keywords matched the following items that are connected to Shanker, Anil

Item Type	Name
Academic Article	Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Academic Article	Promise of Immunotherapy in Lung Cancer.
Academic Article	Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.
Academic Article	Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk.
Academic Article	Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Academic Article	Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
Academic Article	Prospects of combining adoptive cell immunotherapy with bortezomib.
Academic Article	TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.
Academic Article	Sensitizing tumor cells to immune-mediated cytotoxicity.
Academic Article	Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Academic Article	Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Concept	Antineoplastic Agents
Concept	Antineoplastic Agents, Phytogenic
Academic Article	Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.
Academic Article	Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins.
Academic Article	Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.

Search Criteria

Antineoplastic Agents

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support